Lois E. Shepherd
About
Lois E. Shepherd is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine.
According to data from OpenAlex, Lois E. Shepherd has authored 204 papers receiving a total of 15.9k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 70 papers in Cancer Research and 57 papers in Pathology and Forensic Medicine. Recurrent topics in Lois E. Shepherd's work include Breast Cancer Treatment Studies (51 papers), Estrogen and related hormone effects (41 papers) and Lymphoma Diagnosis and Treatment (38 papers). Lois E. Shepherd is often cited by papers focused on Breast Cancer Treatment Studies (51 papers), Estrogen and related hormone effects (41 papers) and Lymphoma Diagnosis and Treatment (38 papers). Lois E. Shepherd collaborates with scholars based in Canada, United States and United Kingdom. Lois E. Shepherd's co-authors include Dongsheng Tu, Kathleen I. Pritchard, Malcolm J. Moore, Daniel J. Sargent, Richard M. Goldberg, Charles A. Schiffer, Haji Chalchal, Frederick R. Appelbaum, James N. Ingle and Derek J. Jonker and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Lois E. Shepherd
197 papers receiving 15.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lois E. Shepherd Canada | 48 | 9.9k | 5.1k | 4.5k | 3.4k | 3.0k | 204 | 15.9k | ||
| Giancarlo Pruneri Italy | 62 | 6.4k 0.6× | 2.8k 0.6× | 5.0k 1.1× | 4.3k 1.2× | 1.7k 0.6× | 356 | 12.4k | ||
| Apostolia M. Tsimberidou United States | 58 | 5.4k 0.5× | 3.4k 0.7× | 4.2k 0.9× | 4.8k 1.4× | 3.3k 1.1× | 445 | 14.5k | ||
| Sjoerd Rodenhuis Netherlands | 60 | 6.0k 0.6× | 2.3k 0.5× | 3.4k 0.8× | 3.6k 1.1× | 4.3k 1.4× | 253 | 12.8k | ||
| Semiglazov Vf Russia | 46 | 8.5k 0.9× | 1.5k 0.3× | 5.6k 1.2× | 2.1k 0.6× | 2.1k 0.7× | 239 | 11.9k | ||
| Gϋnter von Minckwitz Germany | 78 | 16.4k 1.7× | 4.9k 1.0× | 13.2k 2.9× | 4.2k 1.2× | 3.9k 1.3× | 428 | 25.0k | ||
| Gini F. Fleming United States | 60 | 8.2k 0.8× | 2.1k 0.4× | 3.7k 0.8× | 4.1k 1.2× | 2.7k 0.9× | 334 | 16.6k | ||
| Kristine Broglio United States | 52 | 7.2k 0.7× | 2.3k 0.4× | 4.3k 1.0× | 1.9k 0.6× | 2.6k 0.9× | 148 | 12.3k | ||
| Marco Colleoni Italy | 71 | 12.6k 1.3× | 3.2k 0.6× | 10.2k 2.3× | 3.1k 0.9× | 6.5k 2.2× | 421 | 19.5k | ||
| William Novotny United States | 38 | 12.5k 1.3× | 2.2k 0.4× | 3.8k 0.8× | 8.0k 2.3× | 5.7k 1.9× | 110 | 22.6k | ||
| Kathy S. Albain United States | 61 | 11.9k 1.2× | 1.2k 0.2× | 3.8k 0.9× | 2.9k 0.9× | 9.2k 3.1× | 234 | 19.1k |
Countries citing papers authored by Lois E. Shepherd
Since
Specialization
Citations
This map shows the geographic impact of Lois E. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lois E. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lois E. Shepherd more than expected).
Fields of papers citing papers by Lois E. Shepherd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lois E. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lois E. Shepherd. The network helps show where Lois E. Shepherd may publish in the future.
Co-authorship network of co-authors of Lois E. Shepherd
This figure shows the co-authorship network connecting the top 25 collaborators of Lois E. Shepherd. A scholar is included among the top collaborators of Lois E. Shepherd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lois E. Shepherd. Lois E. Shepherd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stewart, Douglas A., John Kuruvilla, David M. Lee, et al.. (2024). Canadian cancer trials group LY .17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP ) versus R‐GDP . British Journal of Haematology. 205(3). 881–890.
2.
Gupta, Arjun, Annette E. Hay, Michael Crump, et al.. (2023). Comparing the time toxicity of cancer treatments in the CCTG LY.12 trial.. Journal of Clinical Oncology. 41(16_suppl). 12135–12135.
3.
Goodwin, Pamela J., Bingshu E. Chen, Karen A. Gelmon, et al.. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology. 41(35). 5356–5362.
4.
Asleh, Karama, Dongsheng Tu, Dongxia Gao, et al.. (2021). Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical Cancer Research. 27(23). 6570–6579.
5.
Ethier, Josée-Lyne, Geoffrey M. Anderson, Peter C. Austin, et al.. (2021). Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. European Journal of Cancer. 149. 117–127.
6.
Cairns, Junmei, James N. Ingle, Tanda M. Dudenkov, et al.. (2020). Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight. 5(16).
7.
Rodríguez‐Romo, Laura, Ralph M. Meyer, Joseph L. Pater, et al.. (2017). Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial. Blood. 130. 4081–4081.
8.
Huang, Jessica, J. W. Chapman, Kim Leitzel, et al.. (2017). Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Research and Treatment. 164(3). 571–580.
9.
Chapman, Judith‐Anne W., Dennis C. Sgroi, Paul E. Goss, et al.. (2016). Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment. 157(1). 101–108.
10.
Ingle, James N., Fang Xie, Matthew J. Ellis, et al.. (2016). Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76(23). 7012–7023.
11.
Kuruvilla, John, David MacDonald, C. Tom Kouroukis, et al.. (2015). Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood. 126(6). 733–738.
12.
Sgroi, Dennis C., Erin Carney, Elizabeth Zarrella, et al.. (2013). Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. JNCI Journal of the National Cancer Institute. 105(14). 1036–1042.
13.
Chia, Stephen, Vivien Bramwell, Dongsheng Tu, et al.. (2012). A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18(16). 4465–4472.
14.
Cheang, Maggie C.U., K. David Voduc, Dongsheng Tu, et al.. (2012). Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18(8). 2402–2412.
15.
O’Malley, F., Stephen Chia, Dongsheng Tu, et al.. (2011). Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Research and Treatment. 128(2). 401–409.
16.
Tu, Dongsheng, Bent Ejlertsen, Maj‐Britt Jensen, et al.. (2011). TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Research and Treatment. 132(1). 225–234.
17.
Pritchard, Kathleen I., Alison F. Munro, Frances P. O’Malley, et al.. (2011). Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Research and Treatment. 131(2). 541–551.
18.
Pritchard, Kathleen I., Lois E. Shepherd, Frances P. O’Malley, et al.. (2006). HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine. 354(20). 2103–2111.
19.
Meyer, Ralph M., Mary Gospodarowicz, Joseph M. Connors, et al.. (2005). Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 23(21). 4634–4642.
20.
Moncrieff, M W, Pauline M. Emerson, Kevin Windebank, & Lois E. Shepherd. (1985). Acute lymphoblastic leukaemia presenting with hypercalcaemia. Clinical & Laboratory Haematology. 7(3). 271–273.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Giancarlo Pruneri Breakdown of academic impact, for papers by Apostolia M. Tsimberidou Breakdown of academic impact, for papers by Sjoerd Rodenhuis Breakdown of academic impact, for papers by Semiglazov Vf Breakdown of academic impact, for papers by Gϋnter von Minckwitz Breakdown of academic impact, for papers by Gini F. Fleming Breakdown of academic impact, for papers by Kristine Broglio Breakdown of academic impact, for papers by Marco Colleoni Breakdown of academic impact, for papers by William Novotny Breakdown of academic impact, for papers by Kathy S. Albain